The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
just arrived in ii account
Very true - although if they buy today they won't need to splash out :) looks like the US will open on the cheap.. But the point is well taken... however if the pound strengthens to the dollar, would that not help the US SP move up, in order to gain parity with the LSE SP? TBH I've no idea (my background is in pharma)
I guess the weakening dollar may not be all bad for US investors - 80p divi used to be 97 cents (£1 = $1.21) but now the same divi is giving $1.13
It’ll be interesting to see Norgine sales, and whether the pandemic increased growth…
I posted on ADVFN a strategy they may want to consider, which focusses more on “switching” patients from IV iron, rather than fight the IV market directly H2H (or toe to toe!). The IV players have a strong force behind them, and rather than just compete against the IV market, a “switch” strategy actually hedges your bets, as even if the IV market grows, so does your potential patient group, given your marketing strategy focus is to switch IV patients to Ferracru very soon after starting IV. The advantages with this focussed strategy is Ferracru will not be viewed by the payers as an “expensive” oral alternative, but a less expensive, more patient friendly, alternative to continued IV treatment. With the EU IV market exceeding 500M and the US IV iron market over 1.2B, even a 10% switch is a big win..
Don’t suggest they give up the fight going H2H, but accept they’re fighting a strong opponent, so just fight smart and use your opponents strength (building the IV market) to your advantage.. The money is long term/maintenance treatment (with Ferracru), so allowing (even encouraging) some short term use with IV may be a good play once the switch strategy is in place. Once their brand is fully established they can move to the next stage of focussing more on direct H2H - one focus at a time though..
I’d like to see a “switch” study (if STX reads these posts!?) and if investigators agree it's a good idea.. evaluating early switch (from IV to Ferracru) vs those who don’t switch.. – it will make it hard for the IV Iron companies to counter this sensible option for patients/physicians and payers.
Thanks for the response Soupdragon - I'll take another look. From experience it's easier logistically to license out by territory (i.e. Nth America, Europe, Asia). By indication is more tricky. If you have multiple companies, funding different development programs, for different indications, the issue becomes one around achieving parity on drug pricing (if working in the same territory, but marketing/selling for different indications).. data sharing can create issues, but easier to rectify..
Just researching, not invested, but looking at the recent RNS - "Nuformix will license its patent estate and know-how on NXP001 in return for development milestone payments and a royalty on any future net sales, capped at £2m per annum" - there doesn't appear to be a mention of the word "significant" when discussing upfront, but I assume the piece that spooked the market was the £2m cap per annum on sales (seems rather low). That said I'm not sure if I'm missing something as the CEO goes on to add "We will now look to finalise the licensing agreement with Oxilio that will provide Nuformix with near term revenue and an opportunity to benefit from the upside of the significant global oncology market" - this is the bit I found confusing. Agree the oncology market is large/growing, but I don't see how they will benefit from this with a £2m cap? Like I say I might be missing something - I'll keep researching
Just started researching IXI but the link below may be of interest (update from Roche yesterday). Assume Roche is the large pharma client mentioned in today's IXI RNS (not many other companies in Phase III for HD)
https://www.roche.com/media/releases/med-cor-2021-03-22b.htm
Hi Pedro - Historically receive the cash dividend early Feb. Only the share divi was issued last week..
Looks like the MM's are walking this down on no volume... - not sure many investors are spooked though, given it closed today at £1.70 (195.4 Tk) on the Dhaka Stock Exchange!
In years gone by, when the company issued a stock divi only, the SP did drop to account for the new shares, but BXP issued the following note at the beginning of the month... although not entirely sure what it means for the SP once we go XD..
BXPHARMA
News Title: BXPHARMA: Dividend Declaration (Additional Information)
News: (Continuation news of BXPHARMA): The Bonus Share is declared out of accumulated profit. The Bonus Share is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post-dividend retained earnings become negative. (end)
Post Date: 2020-11-01
And looks like the AZ vaccine works. Debate about whether it's 70% effective, or it can be optimised to 90%
https://www.bbc.co.uk/news/health-55040635
Cyberduck - looks like the AZ/Oxford vaccine is standard refrigerated - stored at 2-8C - so won't have the supply chain/distribution issues Pfizers vaccine will.. The 30 million vaccines will only vaccinate 15 million people in Bangladesh (less than 10% of the population) so assume this will be targeted at the most vulnerable, health care workers (and maybe those that can pay)... They will need considerably more vaccines in the long term if they aim to undertake a proper vaccination program - so agree with you that 30 million could just be the start?
Article below may be of interest for India.
https://www.newsclick.in/Good-News-Vaccines-but-What-About-Delivery
Hi Cyberduck - Not quite my area of expertise but it will depend how much they can piggy back the vaccine distribution onto their existing supply chain processes/procedures, already set up and in place for their current products. My best guess would be a large proportion of the $30m will be realised as profit. I'm not sure what the storage is for the AZ vaccine, but guessing it's not -80C like the Pfizer version. -80C would no doubt add to the distribution costs..
Looks like it is $1 a vaccine, it was a genuine guess in my previous post..
https://www.thedailystar.net/frontpage/news/buying-3cr-vaccine-doses-govt-signs-deal-indias-sii-beximco-pharma-1990077
p.s. or todays' DSE rise could be that Biden is good for Bangladesh imports?? - although allegedly Trump has won (or was that fake news he released?)
Hi JS -EPS/Q4 came in right on expectation though (we had the heads up of a 20% drop in Q4 with a bounce back in Q1 expected). We'll know later this month if the bounce happened ... I think the DSE rise is also based on the recent AAA rating, reassurance the divi shares are being paid out of realised profit (as I read it on the DSE news that is), and the ongoing prep for the vaccine roll out (although I've no idea how much they will get for each vaccine - could only be $1 for all I know)..
it should be for both LSE (GDRs) and Dhaka ordinary shares
Nice set of results - looks like double digit growth in profits again...
We should see an RNS on Thursday morning giving us the heads up on final year results (June to June 20) + the EPS for the year, and importantly the dividend to be paid. Be interesting to see if we get 30% of profits this year.
RNS may come out later tomorrow, but more likely Thurs 7am..
I think with the progress we're seeing on the Oxford vaccine - and "Jonathan Van-Tam, England’s deputy chief medical officer, has told MPs that the Oxford University vaccine might even be ready by December." - this may help. The vaccine will dwarf Remdesivir. Given the population of Bangladesh is 165 million, even if they aimed for 70% vaccination rate this is still over a 100 million people. If the vaccine is only $10 this equate to a >$1Bn (based on a single dose) - more if they give the 2nd dose booster. Remdesivir may become less important to BXP as time goes on?